Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 21 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

10%

2 trials in Phase 3/4

Results Transparency

43%

3 of 7 completed with results

Key Signals

3 with results100% success

Data Visualizations

Phase Distribution

12Total
Not Applicable (4)
Early P 1 (1)
P 1 (1)
P 2 (4)
P 3 (1)
P 4 (1)

Trial Status

Recruiting8
Completed7
Unknown2
Active Not Recruiting2
Not Yet Recruiting1
Enrolling By Invitation1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 7 completed trials

Clinical Trials (21)

Showing 20 of 20 trials
NCT00001595Recruiting

An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

NCT03831958RecruitingPrimary

Long-Term Follow-Up of Survivors of Pediatric Cushing Disease

NCT07463625RecruitingPrimary

Evaluation of Positron Emission Tomography (PET) With [18F]FET for the Detection of ACTH-Secreting Corticotroph Pituitary Neuroendocrine Tumors.

NCT07460232Early Phase 1Not Yet RecruitingPrimary

FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease

NCT07335315Recruiting

Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors

NCT07108244Not ApplicableEnrolling By InvitationPrimary

Use of [18F]FET PET-MRI to Improve Detection of Pituitary Adenomas in Cushing's Disease

NCT03974789Active Not RecruitingPrimary

Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of Hypercorticisms

NCT03364803Recruiting

Collecting Information About Treatment Results for Patients With Cushing's Syndrome

NCT03774446Phase 2RecruitingPrimary

Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

NCT05971758Phase 2RecruitingPrimary

Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease

NCT04486859Not ApplicableActive Not RecruitingPrimary

Postoperative Thrombosis Prevention in Patients With CD

NCT03621280Phase 3Completed

Open-label Treatment in Cushing's Syndrome

NCT05804669Phase 1Recruiting

A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome

NCT04201444Not ApplicableCompletedPrimary

Hair Cortisol and Cushing's Disease

NCT04374721Not ApplicableUnknown

Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders

NCT00171951Phase 2CompletedPrimary

Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease

NCT01331239Phase 2Completed

Safety and Efficacy of LCI699 in Cushing's Disease Patients

NCT02350153CompletedPrimary

Cushing´s Disease Epidemiology in Sweden

NCT03080181Phase 4CompletedPrimary

Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment

NCT03297892UnknownPrimary

Health Status of the Patients Followed for a Disease of Cushing in the Region Large-West of 1990 to 2015

Scroll to load more

Research Network

Activity Timeline